Nutranomics Announces AES (Assimilation Enhancing System)

New Post Public Reply Private Reply Replies (0) Message Board
MoneyMaker
Nutranomics Announces AES (Assimilation Enhancing System) to be incorporated into Established Pet Food Line

DRAPER, Utah, Oct. 30, 2013 /PRNewswire/ -- Nutranomics, Inc. (OTCBB: NNRX) (OTCQB: NNRX) ("Nutranomics" or the "Company") is pleased to report that Linna Ltd. of Kanagawa, Japan ("Linna") has finalized a plan to include the patented AES™ (Assimilation Enhancing System) enzyme blend from Nutranomics in a premium dog and cat food line.  This marks the first time that the AES™ has been incorporated into the formulation of a pet food product. 

The Company anticipates that AES™ will be included in the formulation of the Cupurera brand of high quality pet food products owned by Linna.  The concept behind the Cupurera dog and cat product line is to provide human quality ingredients for superior pet food.  The Cupurera pet food line is advertised as "The Perfect Natural Pet Food" and includes probiotics and enzymes to improve digestion and nutrient absorption, and is gluten free.

"Since most dog and cat food products are fully cooked, putting the proper balanced enzymes back into the food to improve digestion and nutrient absorption was a good idea not only from a Cupurera marketing perspective, but most importantly for the health of our beloved pets," explained Nutranomics' CEO Dr. Tracy K. Gibbs.  "The planned introduction of our patented AES™ enzyme blend into a complete pet food line has led Nutranomics into an entirely new growing industry with many new high demand product opportunities to potentially develop in the future."

According to American Pet Products Association (APPA), which collects industry statistics from various market research sources, it has been estimated that in 2013, $55.53 billion will be spent on pets in the United States alone, including $21.26 billion on pet food, $13.21 billion on supplies and OTC medicines, and $14.21 on veterinarian care. 

About Nutranomics

Nutranomics is a publicly traded company engaged in research and development of nutritional food products.  In 1997, Nutranomics produced and branded its own product line, and began to sell to the retail outlets and to the public.  Nutranomics has also produced formulas for hundreds of other companies.  Nutranomics' mission is to increase human health and longevity through education and self-awareness.  The Company has sales representatives throughout North America and Asia.

For further information regarding Nutranomics, Inc., please contact our investor relations representatives at ir@nutranomics.com or call toll-free (888) 616-3999.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements."  Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future.  Such forward-looking statements include the Company's plan to execute and accelerate its global sales and marketing plans.   Actual results could differ from those projected in any forward-looking statements due to numerous factors.  Such factors include, among others, the inherent uncertainties associated with developing new products and operating as a development stage company, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, competition in the industry in which we operate and market conditions.  These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law, including the securities laws of the United States.  Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate.  Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.  These statements have not been evaluated by the Food and Drug Administration.  These products are not intended to diagnose, treat, cure or prevent any disease.

SOURCE Nutranomics, Inc.


Copyright 2013 PR Newswire
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Solis Agrosciences Gains Series A Funding to Drive Growth Forward

Updated Category News Views 272

Solis Agrosciences Gains Series A Funding to Drive Growth Forward Solis Agrosciences, a prominent name in the Agtech sector, has announced a significant milestone in its journey of innovation and growth. The company has successfully secured Series A funding from Cultivation Capital, an investment that promises to amplify its business operations and expand its array of...

Continue Reading
Blink Charging: Milestone Achievements and Future Outlook

Updated Category News Views 283

Update on Blink Charging and Its Stock Performance Blink Charging Co. (NASDAQ: BLNK) shares saw an upward trend recently, as the company proudly announced it surpassed 100,000 electric vehicle (EV) chargers sold, deployed, or contracted globally. This significant accomplishment highlights Blink's growth in the EV infrastructure sector. The company's success can be...

Continue Reading
Vanguard Unveils Innovative Active Equity ETF Range

Updated Category News Views 228

Vanguard Launches New Active Equity ETFs Vanguard has recently introduced three active equity ETFs aimed at enhancing investor portfolio options. The newly launched funds are the Vanguard Wellington U.S. Value Active ETF (VUSV), Vanguard Wellington U.S. Growth Active ETF (VUSG), and Vanguard Wellington Dividend Growth Active ETF (VDIG), each managed by the esteemed...

Continue Reading
New COVID-19 Vaccine by Pfizer and BioNTech Shows Promise

Updated Category News Views 244

Revamped Approach to COVID-19 Vaccination In a noteworthy advancement in the fight against the COVID-19 pandemic, Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) are set to introduce an LP.8.1-adapted monovalent COVID-19 vaccine following a positive recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)....

Continue Reading
Gold's Steady Climb Amid Geopolitical Tensions and Economic Shifts

Updated Category News Views 210

Gold Rises for Third Consecutive Session Gold (XAU/USD) has shown a steady increase of over 0.32%, reflecting a notable rise in safe-haven demand driven by global trade tensions. Investors remain concerned about the stability of global supply chains, making gold a popular choice during times of uncertainty. The yellow metal typically shines as a safe-haven asset when...

Continue Reading